Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Phelan, Jody ^a   Coll, Francesc ^a   McNerney, Ruth ^a,b   Ascher, David B ^c   Pires, Douglas E V ^d   Furnham, Nick ^a   Coeck, Nele ^e   Hill Cawthorne, Grant A ^f,g   Nair, Mridul B ^f   Mallard, Kim ^a   Ramsay, Andrew ^h   Campino, Susana ^a   Hibberd, Martin L ^a   Pain, Arnab ^f   Rigouts, Leen ^e,i   Clark, Taane G ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Association study; Convergent evolution; Drug resistance; Genomics; Protein structural modelling; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; BACTERIAL PROTEIN;

ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BACTERIUM ISOLATE; BINDING SITE; CONTROLLED STUDY; CONVERGENT EVOLUTION; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENETIC ASSOCIATION STUDY; GENETIC POLYMORPHISM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT CARE; PROTEIN STABILITY; PROTEIN STRUCTURE; TUBERCULOSIS CONTROL; WHOLE GENOME SEQUENCING; CHEMISTRY; DNA SEQUENCE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR MODEL; MULTIDRUG RESISTANCE; MUTATION; PROTEIN CONFORMATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOME, BACTERIAL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PROTEIN CONFORMATION; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85007428022     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0575-9     Document Type: Article

References (60)

1. World Health Organization. Global tuberculosis report 2014. Geneva; 2014.
2. Gagneux S. Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci. 2012;367:850-9.
3. Galagan JE. Genomic insights into tuberculosis. Nat Rev Genet. 2014;15:307-20.
4. Clark TG, Mallard K, Coll F, Preston M, Assefa S, Harris D, et al. Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One. 2013;8:e83012.
5. Kent PT, Kubica GP. A guide for the level III laboratory. Atlanta: CDC; 1985.
6. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969;41:21-43.
7. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69:331-42.
8. Reynolds MG. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics. 2000;156:1471-81.
9. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Wholegenome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2012;44:106-10.
10. de Vos M, Müller B, Borrell S, Black PA, van Helden PD, Warren RM, et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother. 2013;57:827-32.
11. Coll F, McNerney R, Preston M, Guerra-Assunção JA, Warry A, Hill-Cawthorn G, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med. 2015;7:51.
12. Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, et al. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol. 2015;53:1473-83.
13. Koch A, Mizrahi V, Warner DF. The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin? Emerg Microbes Infect. 2014;3:e17.
14. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341:647-50.
15. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001;104:901-12.
16. Brandis G, Hughes D. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother. 2013;68:2493-7.
17. Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol. 2014;52:2157-62.
18. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999;43:1497-9.
19. Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One. 2013;8:e59414.
20. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province. South Africa Clin Infect Dis. 2011;53:369-72.
21. Schönfeld N, Bergmann T, Vesenbeckh S, Mauch H, Bettermann G, Bauer TT, et al. Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates. Lung India. 2012;29:309-12.
22. Kumar S, Jena L. Understanding rifampicin resistance in tuberculosis through a computational approach. Genomics Inform. 2014;12:276-82.
23. Wahab HA, Choong YS, Ibrahim P, Sadikun A, Scior T. Elucidating isoniazid resistance using molecular modeling. J Chem Inf Model. 2009;49:97-107.
24. Sreevatsan S, Pan X, Stockbauer KE, Williams DL, Kreiswirth BN, Musser JM. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother. 1996;40:1024-6.
25. Tudó G, Rey E, Borrell S, Alcaide F, Codina G, Coll P, et al. Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barcelona. J Antimicrob Chemother. 2010;65:2341-6.
26. Springer B, Kidan YG, Prammananan T, Ellrott K, Böttger EC, Sander P. Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob Agents Chemother. 2001;45:2877-84.
27. Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HI, Barry CE. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55:2515-22.
28. Jagielski T, Ignatowska H, Bakul a Z, Dziewit L, Napiórkowska A, Augustynowicz-Kopec E, et al. Screening for streptomycin resistanceconferring mutations in Mycobacterium tuberculosis clinical isolates from Poland. PLoS One. 2014;9:e100078.
29. Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat Genet. 2013;45:1190-7.
30. Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, Jacobs WR, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother. 1997;41:1677-81.
31. Newport MJ, Finan C. Genome-wide association studies and susceptibility to infectious diseases. Brief Funct Genomics. 2011;10:98-107.
32. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, et al. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis. 2012;16:24-31.
33. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:4812.
34. Kang HM, Zaitlen NA, Wade CM, Kirby A, Heckerman D, Daly MJ, et al. Efficient control of population structure in model organism association mapping. Genetics. 2008;178:1709-23.
35. Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother. 2015;70:686-96.
36. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet. 2013;45:1183-9.
37. Pires DE, Chen J, Blundell TL, Ascher DB. In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity. Sci Rep. 2016;6:19848. doi:10.1038/srep19848.
38. Usher JL, Ascher DB, Pires DE, Milan AM, Blundell TL, Ranganath LR. Analysis of HGD gene mutations in patients with alkaptonuria from the United Kingdom: identification of novel mutations. JIMD Rep. 2015;24:3-11.
39. Nemethova M, Radvanszky J, Kadasi L, Ascher DB, Pires DE, Blundell TL, et al. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on "black bone disease" in Italy. Eur J Hum Genet. 2016;24:66-72.
40. Jafri M, Wake NC, Ascher DB, Pires DE, Gentle D, Morris MR, et al. Germline mutations in the CDKN2B tumor suppressor gene predispose to renal cell carcinoma. Cancer Discov. 2015;5:723-9.
41. van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol. 1991;29:2578-86.
42. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114-20.
43. Li H. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics. 2014;30:2843-51.
44. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078-9.
45. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491-8.
46. Derrien T, Estellé J, Marco Sola S, Knowles DG, Raineri E, Guigó R, et al. Fast computation and applications of genome mappability. PLoS One. 2012;7:e30377.
47. Stamatakis A, Hoover P, Rougemont J. A rapid bootstrap algorithm for the RAxML web servers. Syst Biol. 2008;57:758-71.
48. Coll F, Mallard K, Preston MD, Bentley S, Parkhill J, McNerney R, et al. SpolPred: rapid and accurate prediction of Mycobacterium tuberculosis spoligotypes from short genomic sequences. Bioinformatics. 2012;28:2991-3.
49. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904-9.
50. Reddy TB, Riley R, Wymore F, Montgomery P, DeCaprio D, Engels R, et al. TB database: an integrated platform for tuberculosis research. Nucleic Acids Res. 2009;37(Database issue):D499-508.
51. Lew JM, Kapopoulou A, Jones LM, Cole ST. TubercuList-10 years after. Tuberculosis (Edinb). 2011;91:1-7.
52. Alam MT, Petit RA, Crispell EK, Thornton TA, Conneely KN, Jiang Y, et al. Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association. Genome Biol Evol. 2014;6:1174-85.
53. Bertrand T, Eady NA, Jones JN, Jesmin, Nagy JM, Jamart-Grégoire B, et al. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J Biol Chem. 2004;279:38991-9.
54. Velankar S, van Ginkel G, Alhroub Y, Battle GM, Berrisford JM, Conroy MJ, et al. PDBe: improved accessibility of macromolecular structure data from PDB and EMDB. Nucleic Acids Res. 2016;44:D385-95.
55. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455-61.
56. Pires DE, Ascher DB, Blundell TL. mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics. 2014;30:335-42.
57. Pires DE, Ascher DB, Blundell TL. DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach. Nucleic Acids Res. 2014;42(Web Server issue):W314-9.
58. Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan JZ, et al. Rapid whole genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol. 2015;53:2230-7.
59. Hoffman GE. Correcting for population structure and kinship using the linear mixed model: theory and extensions. PLoS One. 2013;8:e75707.
60. Xu M, Zhou YN, Goldstein BP, Jin DJ. Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J Bacteriol. 2005;187:2783-92.